Milestone Pharmaceuticals Inc
MIST1.820USD
+0.060+3.41%
收盤 02/09, 16:00（美東）報價延遲15分鐘
43.04M總市值
虧損本益比TTM
關於 Milestone Pharmaceuticals Inc 公司
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc簡介
公司代碼MIST
公司名稱Milestone Pharmaceuticals Inc
上市日期May 09, 2019
CEOOliveto (Joseph)
員工數量33
證券類型Ordinary Share
年結日May 09
公司地址420-1111 boul. Dr.-Frederik-Philips
城市MONTREAL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編H4M 2X6
電話15143360444
網址https://www.milestonepharma.com
公司代碼MIST
上市日期May 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Jeffrey Nelson
Mr. Jeffrey Nelson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
其他
68.16%
持股股東
持股股東
佔比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
其他
68.16%
股東類型
持股股東
佔比
Investment Advisor
16.52%
Hedge Fund
14.43%
Venture Capital
6.24%
Research Firm
5.04%
Individual Investor
3.97%
Investment Advisor/Hedge Fund
3.95%
Private Equity
3.78%
Family Office
1.17%
Bank and Trust
0.02%
其他
44.87%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
119
42.67M
50.10%
+14.57M
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Simplify Asset Management Inc
7.96M
9.34%
+5.18M
+186.09%
Sep 30, 2025
Adage Capital Management, L.P.
6.98M
8.19%
+6.98M
--
Sep 30, 2025
Propel Bio Management, LLC
5.12M
6.02%
+4.27M
+502.93%
Jul 11, 2025
Trails Edge Capital Partners LP
3.83M
4.5%
-1.50M
-28.13%
Sep 30, 2025
OrbiMed Advisors, LLC
3.22M
3.78%
+3.22M
--
Sep 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
Morgan Stanley & Co. LLC
2.63M
3.09%
+1.81M
+221.87%
Sep 30, 2025
RTW Investments L.P.
2.51M
2.94%
--
--
Sep 30, 2025
Pathstone
1.00M
1.17%
+1.00M
--
Sep 30, 2025
Two Sigma Investments, LP
900.59K
1.06%
+900.59K
--
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
佔比8.04%
SPDR S&P International Small Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
